Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Bit Digital Inc (BTBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Bit Digital Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Bit Digital Inc trades at $1.58 (market cap $581.34M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 13.8× Bit Digital Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BIO | BTBT | |
|---|---|---|
Market Cap | $8.04B | $581.34M |
Sector | Health | Technology |
52-Week High | $339.75 | $4.22 |
52-Week Low | $241.71 | $1.27 |
Enterprise Value | $7.85B | $870.65M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
BTBT trades at $1.64, down 2.96% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $80.32 million in 2025 with a -145.45% net income margin, missing earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
Despite 100% analyst buy ratings, BTBT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's appeal hinges on turnaround execution and crypto market recovery, but high volatility and operational risks warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
